-
Any New Way to Track Omicron Besides the Sequencing?
Facing the potential high transmissibility, it is quite urgent to implement mass screening in fast and accurate way to avoid “hyperlocal outbreaks”, while rapid antigen test is considered indispensable and effective. Obviously, there's urgent need to rather ramp up sequencing capability or figuring out a rapid way to identify Omicron variant for improving the situation. The new screening scheme with lower cost and higher efficiency is an essential topic especially for the developing countries. -
Fapon Biotech Races to Introduce Omicron Neutralizing Antibodies Titer Testing Solution
Given Omicron's potential higher rate of transmissibility, Fapon Biotech has mobilized resources to accelerate evaluation on the immune evasiveness and vaccine effectiveness on Omicron variant, therefore successfully introduced SARS-CoV-2 Omicron Variant Neutralizing Antibody Titer Testing Solution (ELISA) to effectively screen the immune system evaluation of vaccines. -
Fapon Biotech COVID-19 Testing Raw Materials Experimentally Proved to Be Effective on Omicron Variant Detection
Fapon Biotech has used its antibody pairs for COVID-19 antigen test to conduct an assessment and verification on key variants recommended by WHO. The experiment report accurately results that the antibody pairs promoted by Fapon Biotech can effectively detect the recombinant N protein antigens on the mutant strains, and the data showed consistence with the wild type detection results. It proves that Fapon Biotech raw materials are not affected by the targeted Omicron variant and other mainstream variants. -
Fapon Biotech’s Splendid Appearance on MEDICA 2021
During 15th -18th November, another year of MEDICA 2021 is taking place in Germany as scheduled. Over 50 years, MEDICA has been a leading international trade fair and attracted thousands of exhibitor companies from more than 50 countries to participate every year. As a global leading provider of excellent IVD reagent raw materials and customized solutions, Fapon Biotech is pleased to present its completed COVID-19 testing one-stop solutions and other innovative IVD products at the exhibition stand of Hall3-A81. -
Fapon Biotech's Full Acquisition of Sequlite, Expands Its Strategic Presence in High-Throughput NGS
Fapon Biotech is pleased to announce its full acquisition of Sequlite Genomics, a USA enterprise that focuses on Next-Generation Sequencing (“NGS”). After the share purchase agreement, with a previous investment of 40% share in Sequlite, Fapon Biotech owns 100% Sequlite now. Fapon Biotech takes over and manages Sequlite in all aspects of product research and development and business operation, further deepening its strategic presence in the global NGS business. -
Fapon Biotech’s Another Showcase in 2021 AACC Expo with Excellent IVD Products and Brand New Image
During September 28-30, Fapon Biotech has attended 2021 AACC Annual Scientific Meeting & Clinical Lab Expo (2021 AACC), which is held in Atlanta, GA, USA. While the 2021 AACC will showcase the cutting-edge science and technology shaping the future of laboratory medicine, Fapon Biotech is pleased to bring about its optimized core reagent raw materials as well as newly developed open instruments platforms with our business partners at the exhibition booth of 2754.